Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LR20011
- Development stage
- Phase 2
- Lead developer
- LG Chem
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
LR20011 (also known as GEN-001) is an orally administered live biotherapeutic product (LBP) consisting of a specific strain of *Lactococcus lactis*. Developed by AVEO Oncology (an LG Chem company) in partnership with Genome & Co, LR20011 is designed to modulate the gut microbiome to enhance the host's immune response against solid tumors. The mechanism of action involves the stimulation of immune cells, such as dendritic cells and T cells, and the induction of pro-inflammatory cytokines like IL-12 and IFN-gamma, thereby potentially overcoming resistance to immune checkpoint inhibitors. It is currently being evaluated in clinical trials for various solid tumors, including gastric cancer and biliary tract cancer, typically in combination with PD-1/PD-L1 inhibitors like avelumab or pembrolizumab.
- Other names
- Lactococcus lactis strain GEN-001
Beyond the preview
Go deeper on LR20011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LR20011.